Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...
Your skin becomes more pale than usual, you feel tired, faint or dizzy, get purple spots (that come from superficial bleeding into the skin), show any sign of bleeding, or have a sore throat and high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback